KCNQ1 and lymphovascular invasion are key features in a prognostic classifier for stage II and III colon cancer

• Published in: BMC cancer Vol. 22; no. 1; p. 372
• Main Authors: Uil, Sjoerd H, Coupé, Veerle M H, Bril, Herman, Meijer, Gerrit A, Fijneman, Remond J A, Stockmann, Hein B A C
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.04.2022; BioMed Central; BMC
• Subjects: Adjuvant treatment; Analysis; Biological markers; Biomarker; Biomarkers; Cancer; Care and treatment; CART; Chemotherapy; Classifier; Colon cancer; Colonic Neoplasms - pathology; Colorectal cancer; Diagnosis; Disease-Free Survival; Gene expression; Humans; Immunohistochemistry; KCNQ1; KCNQ1 Potassium Channel - metabolism; KCNQ1 protein; Medical prognosis; Methods; Minimal residual disease; Neoplasm Invasiveness - pathology; Neoplasm Staging; Pathology; Patients; Potassium channels (voltage-gated); Prognosis; Proteins; Regression analysis; Relapse; Retrospective Studies; Risk factors; Surgery; Survival; Survival analysis; Tumor staging; Tumors; Netherlands; Biomarker; Colon cancer; Prognosis; KCNQ1; Lymphovascular invasion; Classifier; CART
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-09473-9

The risk of recurrence after resection of a stage II or III colon cancer, and therefore qualification for adjuvant chemotherapy (ACT), is traditionally based on clinicopathological parameters. However, the parameters used in clinical practice are not able to accurately identify all patients with or without minimal residual disease. Some patients considered 'low-risk' do develop recurrence (undertreatment), whilst other patients receiving ACT might not have developed recurrence at all (overtreatment). We previously analysed tumour tissue expression of 28 protein biomarkers that might improve identification of patients at risk of recurrence. In the present study we aimed to build a prognostic classifier based on these 28 biomarkers and clinicopathological parameters. Classification and regression tree (CART) analysis was used to build a prognostic classifier based on a well described cohort of 386 patients with stage II and III colon cancer. Separate classifiers were built for patients who were or were not treated with ACT. Routine clinicopathological parameters and tumour tissue immunohistochemistry data were included, available for 28 proteins previously published. Classification trees were pruned until lowest misclassification error was obtained. Survival of the identified subgroups was analysed, and robustness of the selected CART variables was assessed by random forest analysis (1000 trees). In patients not treated with ACT, prognosis was estimated best based on expression of KCNQ1. Poor disease-free survival (DFS) was observed in those with loss of expression of KCNQ1 (HR = 3.38 (95% CI 2.12 - 5.40); p < 0.001). In patients treated with ACT, key prognostic factors were lymphovascular invasion (LVI) and expression of KCNQ1. Patients with LVI showed poorest DFS, whilst patients without LVI and high expression of KCNQ1 showed most favourable survival (HR = 7.50 (95% CI 3.57-15.74); p < 0.001). Patients without LVI and loss of expression of KCNQ1 had intermediate survival (HR = 3.91 (95% CI 1.76 - 8.72); p = 0.001). KCNQ1 and LVI were identified as key features in prognostic classifiers for disease-free survival in stage II and III colon cancer patients.